APA (7th ed.) Citation

Doi, T., Takiuchi, H., Ohtsu, A., Fuse, N., Goto, M., Yoshida, M., . . . Tsutsumi, R. (2012). Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. British Journal of Cancer, 106(4), 666. https://doi.org/10.1038/bjc.2011.590

Chicago Style (17th ed.) Citation

Doi, T., et al. "Phase I First-in-human Study of TAK-285, a Novel Investigational Dual HER2/EGFR Inhibitor, in Cancer Patients." British Journal of Cancer 106, no. 4 (2012): 666. https://doi.org/10.1038/bjc.2011.590.

MLA (9th ed.) Citation

Doi, T., et al. "Phase I First-in-human Study of TAK-285, a Novel Investigational Dual HER2/EGFR Inhibitor, in Cancer Patients." British Journal of Cancer, vol. 106, no. 4, 2012, p. 666, https://doi.org/10.1038/bjc.2011.590.